Provided by Tiger Trade Technology Pte. Ltd.

Fate Therapeutics

2.32
+0.02000.87%
Post-market: 2.340.0161+0.69%19:30 EDT
Volume:658.02K
Turnover:1.52M
Market Cap:278.40M
PE:-2.20
High:2.36
Open:2.34
Low:2.27
Close:2.30
52wk High:3.23
52wk Low:0.9500
Shares:120.00M
Float Shares:104.94M
Volume Ratio:0.42
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0528
EPS(LYR):-1.1500
ROE:-60.75%
ROA:-26.22%
PB:1.81
PE(LYR):-2.02

Loading ...

Fate Therapeutics Showcases Clinical Data for FT836 at the American Society of Cancer Oncology Annual Meeting

GlobeNewswire
·
Jun 01

Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Fate Therapeutics (FATE) and Mirum Pharmaceuticals (MIRM)

TIPRANKS
·
May 27

CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts

TIPRANKS
·
May 23

Top Fate Therapeutics Insiders Quietly Unload Shares in Back‑to‑Back Moves

TIPRANKS
·
May 22

Fate Therapeutics Announces Presentations at 2026 Asco and Eular Annual Meetings Highlighting off-the-Shelf Car T-Cell Therapy Pipeline for Cancer and Autoimmune Diseases

THOMSON REUTERS
·
May 21

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

GlobeNewswire
·
May 21

Fate Therapeutics assumed with a Buy at Jefferies

TIPRANKS
·
May 20

Wells Fargo Remains a Hold on Fate Therapeutics (FATE)

TIPRANKS
·
May 14

Fate Therapeutics reports Q1 EPS (26c), consensus (28c)

TIPRANKS
·
May 13

Fate Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028

Reuters
·
May 13

Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate

Benzinga Earnings
·
May 13

Fate Therapeutics Q1 FY26 net loss narrows 17.04% to $31.21 million

Reuters
·
May 13

Fate Therapeutics Q1 Operating Expenses USD 34.299 Million

THOMSON REUTERS
·
May 13

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

GlobeNewswire
·
May 13

Fate Therapeutics says FT819 achieves low disease activity in SLE without chemotherapy conditioning

Reuters
·
May 11

Fate Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
May 08

Piper Sandler Remains a Buy on Fate Therapeutics (FATE)

TIPRANKS
·
May 06

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

GlobeNewswire
·
May 05

Fate Therapeutics posts Phase 1 FT819 lupus data showing B-cell remodeling without chemo conditioning

Reuters
·
May 04